Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.130.60 CHF
Change Today +1.70 / 1.32%
Volume 427.8K
ATLN On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
As of 11:43 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ATLN) Snapshot

Open
SFr.129.50
Previous Close
SFr.128.90
Day High
SFr.131.30
Day Low
SFr.128.80
52 Week High
07/17/15 - SFr.147.00
52 Week Low
01/22/15 - SFr.90.42
Market Cap
14.9B
Average Volume 10 Days
487.3K
EPS TTM
SFr.4.16
Shares Outstanding
114.1M
EX-Date
05/12/15
P/E TM
31.4x
Dividend
SFr.1.30
Dividend Yield
1.00%
Current Stock Chart for ACTELION LTD-REG (ATLN)

Related News

No related news articles were found.

actelion ltd-reg (ATLN) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ATLN) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

2,495 Employees
Last Reported Date: 07/21/15
Founded in 1997

actelion ltd-reg (ATLN) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: SFr.2.7M
Compensation as of Fiscal Year 2014.

actelion ltd-reg (ATLN) Key Developments

DKSH Business Unit Healthcare to Provide Regulatory, Distribution and Logistics Services for Actelion in Hong Kong, Malaysia and Singapore

DKSH Business Unit Healthcare will provide regulatory, distribution and logistics services for Actelion in Hong Kong, Malaysia and Singapore. The agreement initially covers Tracleer, a prescription medicine indicated for patients with certain types of pulmonary arterial hypertension (PAH). Pending product registration in Hong Kong, Malaysia and Singapore, the collaboration may be extended to also include Opsumit (macitentan), an orally available endothelin receptor antagonist (ERA).

Actelion Ltd. Reports Earnings Results for the First Six Months of 2015; Revised Earnings Guidance for the Year of 2015

Actelion Ltd. reported earnings results for the first six months of 2015. For the period, the company reported net revenue of CHF 1,011 million compared to CHF 993 million a year ago. Operating income was CHF 344 million compared to CHF 347 million a year ago. Net income was CHF 287 million compared to CHF 420 million a year ago. Diluted EPS was CHF 2.50 compared to CHF 3.62 a year ago. Core earnings were CHF 423 million compared to CHF 421 million a year ago driven by commercial performance. Core net income was CHF 357 million compared to CHF 378 million a year ago. Diluted core EPS was CHF 3.11 compared to CHF 3.25 a year ago. Operating cash flow was CHF 278 million compared to CHF 259 million a year ago. Capital expenditure was CHF 11 million compared to CHF 12 million a year ago. The company expects to deliver higher profitability in 2015 than originally forecast; as a result, the company is raising full year guidance. Barring unforeseen events, the company now expects 2015 core earnings growth to be in the mid- to high-teen percentage range (at CER, excluding the impact of 2014 US rebate reversals).

Actelion Mulls Acquisitions

Actelion Ltd. (SWX:ATLN) is seeking acquisitions. Actelion said in H1 2015 Earnings Call, “Apart from organic growth opportunities, Actelion has clearly indicated its interest in acquisitions that would create further value for our shareholders.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATLN:VX SFr.130.60 CHF +1.70

ATLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $74.96 USD +1.48
H Lundbeck A/S kr197.30 DKK -1.30
Hikma Pharmaceuticals PLC 2,322 GBp +97.00
Hospira Inc $89.95 USD -0.01
UCB SA €69.44 EUR +2.81
View Industry Companies
 

Industry Analysis

ATLN

Industry Average

Valuation ATLN Industry Range
Price/Earnings 32.0x
Price/Sales 7.1x
Price/Book 10.2x
Price/Cash Flow 28.0x
TEV/Sales 6.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit www.actelion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.